---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-023510"
form_type: "8-K"
ticker: "SCYX"
cik: "0001178253"
company_name: "SCYNEXIS INC"
filed_at: "2022-11-09T23:59:59+00:00"
generated_at: "2026-06-22T00:42:47.037756+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# SCYNEXIS Q3 net loss $29.6M ($0.62/sh), BREXAFEMME rev $1.6M; CEO to retire; PDUFA Nov 30

## Summary
- Q3 2022 net loss $29.6M vs $0.6M loss in Q3 2021; basic loss per share $0.62 vs $0.02.
- BREXAFEMME net revenue $1.6M (up 23% QoQ); 5,785 total prescriptions written, up 13% vs Q2.
- Cash, equivalents and short-term investments $96.1M; projected runway into Q2 2024.
- CEO Marco Taglietti to retire Dec 31, 2022; David Angulo (CMO) to become CEO effective Jan 1, 2023.
- PDUFA date Nov 30, 2022 for BREXAFEMME sNDA for prevention of recurrent VVC; company seeking commercialization partner.

## SEC filing metadata
- accession: 0000950170-22-023510
- form_type: 8-K
- ticker: SCYX
- cik: 0001178253
- company_name: SCYNEXIS INC
- filed_at: 2022-11-09T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1178253/000095017022023510/0000950170-22-023510-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1178253/000095017022023510/scyx-20221109.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-023510
- JSON: https://secwatch.observer/filing/0000950170-22-023510.json
- Plain text: https://secwatch.observer/filing/0000950170-22-023510.txt

## Key facts
- Earnings Releases
  SCYNEXIS INC reported the third quarter ended September 30, 2022 results: revenue $1.6 million.
  - Period: the third quarter ended September 30, 2022
  - Revenue: $1.6 million
  - Result: reported results
  source text: the Board effective January 1, 2023. • BREXAFEMME ® (ibrexafungerp tablets) prescriptions continued to grow in Q3 2022, increasing 13% over Q2 2022, generating net revenues of $1.6 million in Q3 2022, compared to $1.3 million in Q2 2022. • Coverage for BREXAFEMME increased to 130 million, or 70% of commercially insured lives, with the addition of a major national
  evidence_url: https://www.sec.gov/Archives/edgar/data/1178253/000095017022023510/0000950170-22-023510-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.